ESG risk score 19.02
Environmental score 2.11
Social score 11.85
Governance score 5.07
ESG risk category Low
Negligible Low Med High Severe
0-10 10-20 20-30 30-40 40+
Swedish Orphan Biovitrum AB
000.00
0.00 / 0.00%
00:00:00
52 week range
0000.00 000.00
Symbol SOBIV:xome
Currency SEK
NASDAQ OMX Stockholm
Open Closed
15 minutes delayed
Data provided by 
This information is not currently available for this instrument. Refresh the page or try again later.
Want to start investing?
Trade stocks with a broker trusted by over 1.5 million clients. Investing involves risk. You may lose some or all of your investment.
Chart
This information is not currently available for this instrument. Refresh the page or try again later.
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
This information is not currently available for this instrument. Refresh the page or try again later.
Returns
Year to date (YTD) 20.43%
1 year 41.63%
3 years 73.75%
Data provided by 
Key stats
Price/earnings (LTM) 287.79
Dividend yield (LTM) -
EPS (LTM) 1.39
Volatility (30 days) -
Data provided by
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Data provided by 
/ 
/ Financials
Q1 Q2 Q3 Q4
Income statement
Revenue XXXXXXX XXXXXXX XXXXXXX XXXXXXX
EBITDA XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Net income XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Balance sheet
Total assets XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Total debt XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Ratios
Price/sales XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Earnings per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Dividend per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Return on equity XXXXXXX XXXXXXX XXXXXXX XXXXXXX
About Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Sector Healthcare
Industry -
Market cap 141bn
Data provided by /
/ Frequently asked questions
To buy Swedish Orphan Biovitrum AB stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Swedish Orphan Biovitrum AB by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Swedish Orphan Biovitrum AB is SOBIV:xome. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Swedish Orphan Biovitrum AB has its primary listing on NASDAQ OMX Stockholm. You can trade Swedish Orphan Biovitrum AB with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Swedish Orphan Biovitrum AB is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Swedish Orphan Biovitrum AB as part of a broader investment portfolio.